**CANDIDATURA IN VISTA DEL CONFERIMENTO DEL GRADO DI PROFESSORE TITOLARE**

**Dr. med. XXX YYYY**

**Funzione**

**Servizio**

**Ospedale**

**Luogo**

**Nazione**

**CURRICULUM VITAE PROFESSIONALE**

**Dati anagrafici**

Data di nascita: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Luogo di origine: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Nazionalità: \_\_\_\_\_\_\_\_\_\_\_\_\_\_

Email: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Indirizzo professionale: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Indirizzo privato: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Formazione preuniversitaria**

-19XX-19XX Scuole elementari, Luogo (Nazione)

-19XX-19XX Scuole Medie, Luogo (Nazione)

-19XX-19XX Liceo Cantonale, Luogo (Nazione)

**Formazione universitaria**

-19XX-19XX Università di Luogo (Nazione)

-19XX-20XX Università di Luogo (Nazione)

**Conoscenze linguistiche**

XXXX (lingua madre), YYYYY, ZZZZZ

**Posizioni postuniversitarie**

- 1.1.20XX-31.12.20XX: medico assistente, Reparto XXX, Ospedale XXXX, Nazione (direttore: Prof. Dr. med. XXXXX).

- 1.1.20XX-31.12.20XX: medico capo-clinica, Reparto XXX, Ospedale XXXX, Nazione (direttore: Prof. Dr. XXXX).

- da 1.1.20XX: medico caposervizio, Servizio XXXX, Ospedale XXXX, Luogo Nazione (direttore: Dr. med XXXX).

Formazione di ricerca

- Laboratorio di ricerca XXXXXX, Ospedale, Luogo, Nazione (responsabile: Prof. Dr. XXXX).

- Laboratorio di ricerche XXXXX , Clinica XXXX, Luogo, Nazione (responsabile: Prof. Dr. XXXXX).

**Diplomi**

- 19XX Maturità XXXXXXXXXXX

- 20XX Diploma XXXXXXXXXXXXX

- 20XX Dottorato XXXXXXXX

- 20XX Titolo specialità XXXXXXXXX

- 20XX Venia legendi (libera docenza) – Università XXXX

- 20XX Corso di didattica medica “teach the teacher” Luogo

**Membro delle seguenti società professionali**

- Società svizzera XXX

- Società svizzera VVVV

- Società europea YYYY

**Consulenze per riviste scientifiche**

**- “Reviewer”**

### Nome della rivista – nome della rivista – nome della rivista.

**- Comitato di redazione (“Editorial Board”) di riviste scientifiche**

### XXXXX (20XX-20XX)

**Riconoscimenti**

Premio XXXX 20XX della Società Svizzera di XXXXX

**Esperienza didattica (2 anni prima della candidature)**

- Relatore ai corsi di aggiornamento interni del Servizio di XXXX, Ospedale XXXXX, Luogo (circa 6 presentazioni all’anno)

- Relatore al corso di aggiornamento in XXXXXX del Luogo (20XX)

- Presentazioni orali al congresso della Società XXXX (20XX e 20XX)

- Presentazione di 2 poster all’American XXXX Soociety (Luogo, 20XX)

- Case-based learning settimanale dell’Ospedale XXXXX (direzione: Prof. Dr. med. XXXX)

**PRODUZIONE SCIENTIFICA**

**• Direzione di tesi di master:** X. YYYY (20XX), Y. ZZZZZ (20XX), Z. VVVVV (20XX), V. WWW(20XX)

**• Direzione di tesi (MD):** Y. XXX (20XX), Z. YYYY (20XX), V. WWW (20XX)

**• Fondi di ricerca**

- 20XX: Fondo di ricerca della Società XXXX (Tema; CHF XX’XXX.00)

- 20XX: Borsa della Fondazione XXX (CH XX’XXX)

**Lavori scientifici pubblicati in riviste con politica editoriale**

**• Fattore di Hirsch (Scopus, verificato il XX.X.XX): Y**

**• Lavori originali e reviews sistematiche**

**Prima del conferimento della venia legendi**

1. **Viviani CF**, Mascetti L, Bettazzi A, Simoni GD, Taglioni A, Syrén ML, Nordio F. Pregnancy in inherited hypokalemic salt-losing renal tubular disorder. Obstet Gynecol 117: 512-516, 2002. Impact factor/maximum ranking 2016: 4.982 / 0.951
2. **Viviani CF**, Zgraffen L, Faré PB, Müller SA, Simoni GD, Fossoni EF, Amoruso C. Palatability of crushed ß-blockers, converting enzyme inhibitors and thiazides. J Clin Pharm Ther 37: 544-546, 2003. Impact factor/maximum ranking 2016: 1.661 / 0.227
3. Bullo M, Tschumi S, Bucher BS, **Viviani CF**, Simoni GD. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension 60: 444-450, 2003. Impact factor/maximum ranking 2016: 6.823 / 0.969
4. Terrorista L, Müller SAG, Camozzi P, Zgraggen L, Simoni GD, **Viviani CF**, Torino GP. Unusual eruptions associated with Mycoplasma pneumoniae respiratory Infections: review of the literature. Dermatology 231: 152-157, 2003. Impact factor/maximum ranking 2016: 1.958 / 0.556
5. **Viviani CF**, Janett S, Camozzi P, Peeters GGAM, Müller SAG, Simoni GD, Simonari B, Torino GP. Hypomagnesemia induced by long-term treatment with proton-pump inhibitors. Gastroenterol Res Pract 2015:951768, 2004. Impact factor/maximum ranking 2016: 1.859 / 0.212
6. Müller C, Camozzi P, Renzo S, Müller SAG, Simoni GD, **Viviani CF,** Torino GP. Breastfeeding-associated hypernatremia: a systematic review of the literature. J Hum Lact 32:67–74, 2016. Impact factor/maximum ranking 2016: 1.836 / 0.849
7. **Viviani CF**, Helbling R, Müller SAG, Simoni GD, Camozzi P, Torino GP. Gallbladder and pancreas in Henoch-Schönlein purpura: Systematic review of the literature. J Pediatr Gastroenterol Nutr 62:457-461,2005. Impact factor/maximum ranking 2016: 2.752 / 0.823
8. Ferrarini A, Benetton C, Camozzov P, Ostinelli A, Simoni GD, Torino GP, **Viviani CF**, Müller SAG. Acute hemorrhagic edema of young children: a prospective case series. Eur J Pediatr 175:557-561,2006. Impact factor/maximum ranking 2016: 2.242 / 0.669
9. **Viviani CF**, Viano FA, Mazzoni MBM, Peeters GGAM, Fossoni EF, Camozzi P, Torino GP. Micro- and macroscopic hematuria caused by renal vein entrapment: systematic review of the literature. Pediatr Nephrol 31:175-184, 2008. Impact factor/maximum ranking 2016: 2.627 / 0.79
10. Santini M, Torino GP, Simoni GD, Fossoni EF, **Viviani CF,** Müller SAG. Magnesium in cystic fibrosis – Systematic review of the literature. Pediatr Pulmonol 51:196-202, 2008. Impact factor/maximum ranking 2016: 3.157 / 0.887
11. Santini M, Müller SAG, Simoni GD, Stettbacher A, **Viviani CF,** Muggli F. Clustering of cardiovascular disease risk factors among male youths in Southern Switzerland: preliminary study. Swiss Med Wkly: accepted for publication. Swiss Med Wkly 146:w14338, 2008. Impact factor/maximum ranking 2016: 1.928 / 0.61
12. **Viviani CF**, Müller SAG, Helbling R, Simoni GD, Torino GP. Pancreatitis and cholecystitis in primary acute symptomatic Epstein-Barr virus infection – Systematic review of the literature. J Clin Virol 82:51–55, 2008. Impact factor/maximum ranking 2016: 3.101 / 0.571
13. Saponetta A, Gondoni E, Cavallari R, Collina AM, Lombardi F, **Viviani CF**. Sporadic acute benign calf myositis: Systematic literature review. Neuromuscul Disord 28: 443-449, 2009. Impact factor/maximum ranking 2016: 2.487 / 0.457
14. Alentini P, Giavarini A, **Viviani CF**, Gondoni E, Cavallari R, Collina AM, Lombardi F. Cardiovascular profile of propranolol after multiple dosing in infantile hemangioma. J Virol 156:126-131, 20010. Impact factor/maximum ranking 2016: 4.368 / 0.8

**Dopo del conferimento della venia legendi**

1. Lavoratori CM, Romani GP, Lavastoviglie SAG, **Viviani CF**, Biancardi MG, Simoni GD, Giannoni O. Hyperammonemia associated with recessive polycystic kidney disease: a systematic review. Pediatr Nephrol. 2010;33(3):485-491. Impact factor/maximum ranking 2016: 2.627 / 0.79
2. Bianchi MG, Bettinardi A, Casez JP, Basilio E, Menta MG, Spichiger I, **Viviani CF**, Bigoni M, Jäger P. Evidence for disturbed regulation of calciotropic hormone metabolism in sarcoidosis. J Clin Endocrinol Metab 2011;80: 224-228. Impact factor/maximum ranking 2016: 5.789 / 0.866
3. Hafen G, Laux-End R, Truttmann AC, Schibler A, McGuigan JAS, **Viviani CF**. Circvulating ionized magnesium during hyperventilation in healthy subjects. Clin Sci 2011;91: 347-351. Impact factor/maximum ranking 2016: 5.22 / 0.88
4. Villiger RM, von Vigier RO, Ramelli GP, Hassink RI, **Viviani CF**. 42 cases of erythema nodosum in sarcoidosis. Eur J Pediatr 2012;158: 929-932. Impact factor/maximum ranking 2016: 2.242 / 0.669
5. Leeaphorn N, Stokes MB, Ungprasert P, Lecatess W, **Viviani CF**. Management of granulomatous interstitial nephritis with mycophenolate mofetil: a multicenter inquiry. Am J Kidney Dis 2012;63:696-701. Impact factor/maximum ranking 2016: 7.129 / 0.934
6. Hamzeh N, Voelker A, Forssén A, Gottschall EB, Rose C, Mroz P, Maier LA, **Viviani CF**. Efficacy of mycophenolate mofetil in sarcoidosis: preliminary data. Respir Med 2013;108:1663-1669. Impact factor/maximum ranking 2016: 3.31 / 0.701
7. Tomnar RP, Rossi R, **Viviani CF**. Metabolic acidosis due to inhaled salbutamol: systematic literature review. Respir Med 2015;111:103-109. Impact factor/maximum ranking 2016: 3.31 / 0.701
8. **Viviani CF**,William JH, Scott DJ, Lee A, Howell MM, Cello DA, Mukammal AB. Proton-pump inhibitor use is associated with low magnesium concentrations in patients affected with asthma. Am J Respir Med 2016;119:345-352. Impact factor/maximum ranking 2016: 7.129 / 0.934
9. Snider MA, Wan JA, Kink R, Gilmores A, Arnold SR, **Viviani CF.** A randomized trial comparing metered dose inhalers and breath actuated nebulizers. J Emerg Med 2017;55:77-84. Impact factor/maximum ranking 2016:1.207 / 0.423
10. **Viviani CF**, Howe A, Jaalam K, Ahmad B, Sheng C, Rahman D. The use of capnography to monitor non-intubated patients presenting with asthma. J Emerg Med 2018;41:81-87. Impact factor/maximum ranking 2016:1.207 / 0.423

**• Case reports – letters**

**Prima del conferimento della venia legendi**

1. Torino GP, Dellepiane RM, Castellazzi ML, Mazzoni MBM, **Viviani CF**, Fossoni EF. Episodic idiopathic systemic capillary leak syndrome in a girl. Pediatr Int 2006;55: e81-e82. Impact factor/maximum ranking 2016: 0.86 / 0.121
2. **Viviani CF**, Müller SA, Simoni GD. Using ibuprofen to treat croup in six children presented to an emergency unit. Acta Paediatr 2007;102: e352. Impact factor/maximum ranking 2016: 2.58 / 0.782
3. **Viviani CF**, Kessler C, Tschumi S, Simoni GD**.** New-onset bone marrow aplasia in a 15-year-old adolescent with pauci-immune crescentic glomerulonephritis. Acta Paediatr 30:1265-1268, 2015. Impact factor/maximum ranking 2016: 2.58 / 0.782
4. **Viviani CF**, Camozzai P, Faré PB, Müllergno C, Torino GP, Fossoni EF, Müller SAG. Italo-Swiss "Chalk and blackboard interactive 2-day workshop" - participants feedback. Ital J Pediatr 2009;41:60. Impact factor/maximum ranking 2016: 1.776 / 0.532

**Dopo il conferimento della venia legendi**

1. **Viviani CF**, Camozzai P. Lactate clearance and beta-agonist-induced elevated lactates in asthma. Internet J Pneumol 2015;4:127-131. Impact factor/maximum ranking 2016: 0.314 / 0.234

**• Reviews narrative**

**Prima del conferimento della venia legendi**

1. Bucher BS, Ferrarini A, **Viviani CF**, Weber N, Bullo M, Simoni GD. Primary hypertension in childhood. J Hypertens 2008;15: 444-452. Impact factor/maximum ranking 2016: 4.092 / 0.846
2. Müller SAG, Simoni GD, Bianchetti AA, **Viviani CF**, Ferrarini A. Prevention of vitamin D insufficiency in Switzerland: A never-ending story. Int J Pharm 2008;457: 353-356. Impact factor/maximum ranking 2016: 3.862 /0.827
3. Müller SAG, **Viviani CF**, Simoni GD. Salt intake in children and its consequences on blood pressure. Pediatr Nephrol 2010;30:1389–1396 Impact factor/maximum ranking 2016: 2.627 / 0.79
4. **Viviani CF,** Bucher BS, Simoni GD. Controversy about hypertension screening in children: a clinical perspective. J Hypertens 2010;33:1356-1358. Impact factor/maximum ranking 2016: 4.092 / 0.846
5. **Viviani CF**, Santon M, Müller SAG, Camozzov P, Giannelli O, Torino GP, Simoni GD, Fossoni EF, Faré PB. The great fluid debate: saline or balanced salt solutions? Ital J Pediatr 41:47, 2016. Impact factor/maximum ranking 2016: 1.776 / 0.532
6. Bertinotti A, Torino GP, Simoncelli GD, Fossoni EF, Faré PB, **Viviani CF**, Müller SAG. Na+, K+, Cl-, acid-base or H2O homeostasis in infants with bronchiolitis: narrative review. Pediatr Nephrol 31:1403–1409, 2017. Impact factor/maximum ranking 2016: 2.627 / 0.79

**Dopo il conferimento della venia legendi**

1. Bertinotti A, Brescia GP, Fossoni EF, Faré PB, **Viviani CF**. Sarcoidosis: current management. Pneumology 2017;23:555-561. Impact factor/maximum ranking 2016: 2.500 / 0.600
2. **Viviani CF**, James WE, Baughman R. Treatment of sarcoidosis: grading the evidence.m Expert Rev Clin Pharmacol. 2018;30:51-63. Impact factor/maximum ranking 2016: 2.758 / 0.569

23/6/2018